| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiology | 25 | 2024 | 170 | 2.520 |
Why?
|
| Angioplasty, Balloon, Coronary | 26 | 2014 | 171 | 1.380 |
Why?
|
| Cardiac Catheterization | 20 | 2014 | 293 | 1.370 |
Why?
|
| Angioplasty | 4 | 2012 | 53 | 0.810 |
Why?
|
| Coronary Angiography | 19 | 2015 | 212 | 0.680 |
Why?
|
| Heart Valve Prosthesis Implantation | 8 | 2014 | 171 | 0.660 |
Why?
|
| Stents | 7 | 2010 | 498 | 0.600 |
Why?
|
| Coronary Disease | 14 | 2002 | 246 | 0.560 |
Why?
|
| Coronary Artery Disease | 9 | 2015 | 324 | 0.500 |
Why?
|
| Clinical Competence | 11 | 2014 | 727 | 0.490 |
Why?
|
| Societies, Medical | 12 | 2024 | 400 | 0.490 |
Why?
|
| Hospitals | 6 | 2014 | 386 | 0.460 |
Why?
|
| Coronary Vessels | 8 | 2012 | 125 | 0.420 |
Why?
|
| Myocardial Infarction | 9 | 2009 | 919 | 0.420 |
Why?
|
| Coronary Artery Bypass | 10 | 2010 | 292 | 0.400 |
Why?
|
| Heart Valve Diseases | 4 | 2014 | 93 | 0.390 |
Why?
|
| Mitral Valve | 4 | 2014 | 126 | 0.380 |
Why?
|
| Aortic Valve Stenosis | 5 | 2014 | 190 | 0.380 |
Why?
|
| Patient Selection | 7 | 2011 | 485 | 0.350 |
Why?
|
| Cardiovascular Agents | 3 | 2007 | 106 | 0.330 |
Why?
|
| Carotid Stenosis | 1 | 2010 | 100 | 0.290 |
Why?
|
| Patient Care Team | 8 | 2014 | 335 | 0.290 |
Why?
|
| Radiology, Interventional | 3 | 2011 | 31 | 0.270 |
Why?
|
| Thrombolytic Therapy | 5 | 2007 | 195 | 0.260 |
Why?
|
| Humans | 72 | 2024 | 65141 | 0.260 |
Why?
|
| Medical Informatics | 1 | 2008 | 72 | 0.260 |
Why?
|
| Treatment Outcome | 22 | 2022 | 5790 | 0.260 |
Why?
|
| Patient Education as Topic | 2 | 2008 | 481 | 0.260 |
Why?
|
| Quality Assurance, Health Care | 3 | 2014 | 252 | 0.250 |
Why?
|
| Practice Guidelines as Topic | 5 | 2014 | 736 | 0.240 |
Why?
|
| Acute Coronary Syndrome | 3 | 2013 | 253 | 0.230 |
Why?
|
| Thrombosis | 2 | 2007 | 206 | 0.230 |
Why?
|
| Attitude of Health Personnel | 2 | 2007 | 627 | 0.230 |
Why?
|
| Public Health | 1 | 2007 | 186 | 0.230 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2007 | 767 | 0.230 |
Why?
|
| Health Policy | 3 | 2016 | 191 | 0.220 |
Why?
|
| Internet | 1 | 2008 | 468 | 0.210 |
Why?
|
| Coitus | 1 | 2004 | 15 | 0.210 |
Why?
|
| Physician-Patient Relations | 1 | 2007 | 427 | 0.200 |
Why?
|
| American Heart Association | 6 | 2014 | 128 | 0.200 |
Why?
|
| Evidence-Based Medicine | 8 | 2012 | 460 | 0.190 |
Why?
|
| Risk Assessment | 11 | 2015 | 2102 | 0.190 |
Why?
|
| Obesity, Morbid | 1 | 2004 | 93 | 0.190 |
Why?
|
| Health Promotion | 1 | 2007 | 516 | 0.190 |
Why?
|
| Cardiovascular System | 1 | 2022 | 41 | 0.170 |
Why?
|
| Program Development | 4 | 2014 | 208 | 0.170 |
Why?
|
| United States | 15 | 2016 | 8098 | 0.160 |
Why?
|
| Graft Occlusion, Vascular | 2 | 2010 | 60 | 0.160 |
Why?
|
| Ambulatory Care | 2 | 2015 | 317 | 0.160 |
Why?
|
| Risk Factors | 11 | 2011 | 5430 | 0.150 |
Why?
|
| Cardiovascular Diseases | 4 | 2010 | 863 | 0.150 |
Why?
|
| Coronary Thrombosis | 2 | 2007 | 21 | 0.150 |
Why?
|
| Radiography, Interventional | 2 | 2011 | 82 | 0.150 |
Why?
|
| Women's Health | 3 | 2015 | 374 | 0.150 |
Why?
|
| Occupational Exposure | 3 | 2011 | 319 | 0.150 |
Why?
|
| Hemorrhage | 2 | 2000 | 285 | 0.150 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 1999 | 40 | 0.150 |
Why?
|
| Myocardial Revascularization | 4 | 2010 | 78 | 0.140 |
Why?
|
| Platelet Aggregation Inhibitors | 4 | 2007 | 235 | 0.140 |
Why?
|
| Registries | 7 | 2010 | 925 | 0.140 |
Why?
|
| Ultrasonography, Interventional | 4 | 2013 | 123 | 0.140 |
Why?
|
| Quality of Health Care | 6 | 2012 | 528 | 0.140 |
Why?
|
| Postoperative Complications | 4 | 2012 | 1322 | 0.140 |
Why?
|
| Male | 36 | 2013 | 31055 | 0.130 |
Why?
|
| Heart Ventricles | 1 | 1999 | 267 | 0.130 |
Why?
|
| Middle Aged | 28 | 2015 | 18273 | 0.120 |
Why?
|
| Health Facilities | 2 | 2014 | 44 | 0.120 |
Why?
|
| Quality Improvement | 2 | 2011 | 464 | 0.120 |
Why?
|
| Medical Staff Privileges | 5 | 2014 | 8 | 0.120 |
Why?
|
| Female | 34 | 2015 | 34030 | 0.120 |
Why?
|
| Terminology as Topic | 2 | 2013 | 144 | 0.110 |
Why?
|
| Abnormalities, Radiation-Induced | 2 | 2011 | 2 | 0.110 |
Why?
|
| Radiation Monitoring | 2 | 2011 | 4 | 0.110 |
Why?
|
| Clinical Decision-Making | 1 | 2015 | 169 | 0.100 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2011 | 26 | 0.100 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2016 | 142 | 0.100 |
Why?
|
| Radiation Protection | 2 | 2011 | 26 | 0.100 |
Why?
|
| Certification | 1 | 2014 | 58 | 0.100 |
Why?
|
| Time Factors | 8 | 2012 | 3762 | 0.100 |
Why?
|
| Fetus | 2 | 2011 | 102 | 0.100 |
Why?
|
| Electrocardiography | 5 | 2009 | 554 | 0.100 |
Why?
|
| Radiation Dosage | 2 | 2011 | 139 | 0.100 |
Why?
|
| Sex Factors | 6 | 2010 | 991 | 0.100 |
Why?
|
| Documentation | 1 | 2014 | 134 | 0.100 |
Why?
|
| Prosthesis Design | 3 | 2010 | 219 | 0.100 |
Why?
|
| Fractional Flow Reserve, Myocardial | 1 | 2013 | 20 | 0.100 |
Why?
|
| Angiography | 4 | 2004 | 154 | 0.090 |
Why?
|
| Patient Care | 1 | 2013 | 79 | 0.090 |
Why?
|
| Knowledge Bases | 4 | 2012 | 6 | 0.090 |
Why?
|
| Endarterectomy, Carotid | 2 | 2010 | 79 | 0.090 |
Why?
|
| Pulmonary Wedge Pressure | 2 | 1991 | 27 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2007 | 805 | 0.090 |
Why?
|
| Thoracic Injuries | 1 | 1991 | 46 | 0.080 |
Why?
|
| Quality Indicators, Health Care | 2 | 2011 | 346 | 0.080 |
Why?
|
| Coronary Vessel Anomalies | 1 | 1991 | 23 | 0.080 |
Why?
|
| Wounds, Nonpenetrating | 1 | 1991 | 116 | 0.080 |
Why?
|
| Saphenous Vein | 1 | 2010 | 51 | 0.080 |
Why?
|
| Education, Medical, Continuing | 1 | 2011 | 92 | 0.080 |
Why?
|
| Length of Stay | 4 | 2009 | 827 | 0.080 |
Why?
|
| Algorithms | 1 | 2015 | 1048 | 0.080 |
Why?
|
| Heart Atria | 1 | 1991 | 137 | 0.080 |
Why?
|
| Women's Health Services | 1 | 2010 | 30 | 0.080 |
Why?
|
| Women | 1 | 2010 | 43 | 0.080 |
Why?
|
| Career Choice | 3 | 2022 | 126 | 0.080 |
Why?
|
| Mitral Valve Insufficiency | 1 | 1991 | 98 | 0.080 |
Why?
|
| Research Design | 1 | 2013 | 588 | 0.080 |
Why?
|
| Primary Health Care | 1 | 2015 | 722 | 0.080 |
Why?
|
| Stroke | 2 | 2010 | 1211 | 0.080 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2011 | 155 | 0.080 |
Why?
|
| Pregnancy | 3 | 2011 | 2374 | 0.070 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2013 | 225 | 0.070 |
Why?
|
| Multivariate Analysis | 5 | 2007 | 930 | 0.070 |
Why?
|
| Occupational Health | 1 | 2011 | 193 | 0.070 |
Why?
|
| Cardiomyopathies | 1 | 1991 | 138 | 0.070 |
Why?
|
| Aged | 20 | 2012 | 14963 | 0.070 |
Why?
|
| Occupational Diseases | 1 | 2011 | 266 | 0.070 |
Why?
|
| Atherectomy, Coronary | 3 | 2003 | 12 | 0.070 |
Why?
|
| Follow-Up Studies | 9 | 2002 | 2484 | 0.070 |
Why?
|
| Severity of Illness Index | 3 | 2010 | 1559 | 0.070 |
Why?
|
| Patient Readmission | 1 | 2012 | 448 | 0.070 |
Why?
|
| Oxygen | 1 | 2009 | 319 | 0.070 |
Why?
|
| Guideline Adherence | 1 | 2010 | 307 | 0.070 |
Why?
|
| Hypothermia, Induced | 1 | 2007 | 40 | 0.060 |
Why?
|
| Contrast Media | 1 | 2009 | 432 | 0.060 |
Why?
|
| Drug-Eluting Stents | 1 | 2007 | 68 | 0.060 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2007 | 45 | 0.060 |
Why?
|
| Peptides | 2 | 2002 | 591 | 0.060 |
Why?
|
| Coronary Restenosis | 2 | 2003 | 21 | 0.060 |
Why?
|
| Predictive Value of Tests | 4 | 2015 | 1113 | 0.060 |
Why?
|
| Myocardial Ischemia | 3 | 2002 | 118 | 0.060 |
Why?
|
| Prospective Studies | 6 | 2015 | 3310 | 0.060 |
Why?
|
| Advisory Committees | 3 | 2013 | 111 | 0.060 |
Why?
|
| Observer Variation | 2 | 2012 | 216 | 0.060 |
Why?
|
| Anticoagulants | 2 | 2000 | 525 | 0.060 |
Why?
|
| Patient Discharge | 1 | 2009 | 519 | 0.060 |
Why?
|
| Periodicals as Topic | 1 | 2008 | 178 | 0.060 |
Why?
|
| Fibrinolytic Agents | 2 | 2000 | 178 | 0.060 |
Why?
|
| Credentialing | 1 | 2005 | 15 | 0.060 |
Why?
|
| Healthcare Disparities | 1 | 2010 | 407 | 0.050 |
Why?
|
| Vascular Patency | 3 | 2010 | 134 | 0.050 |
Why?
|
| Carotid Artery Diseases | 1 | 2005 | 61 | 0.050 |
Why?
|
| Oximes | 2 | 1994 | 11 | 0.050 |
Why?
|
| Organotechnetium Compounds | 2 | 1994 | 28 | 0.050 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2002 | 25 | 0.050 |
Why?
|
| Cholesterol | 2 | 2002 | 261 | 0.050 |
Why?
|
| Adult | 9 | 2011 | 17358 | 0.050 |
Why?
|
| Dominican Republic | 1 | 2022 | 23 | 0.050 |
Why?
|
| Angioplasty, Balloon | 1 | 2002 | 55 | 0.050 |
Why?
|
| Lipoproteins | 1 | 2002 | 85 | 0.050 |
Why?
|
| Physicians | 1 | 2008 | 477 | 0.050 |
Why?
|
| Echocardiography | 2 | 1999 | 510 | 0.050 |
Why?
|
| Retirement | 1 | 2022 | 21 | 0.050 |
Why?
|
| Stroke Volume | 3 | 2001 | 342 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2004 | 991 | 0.040 |
Why?
|
| Career Mobility | 1 | 2022 | 63 | 0.040 |
Why?
|
| Angina Pectoris | 4 | 2002 | 35 | 0.040 |
Why?
|
| Hemodynamics | 3 | 1996 | 251 | 0.040 |
Why?
|
| Pain | 1 | 2004 | 399 | 0.040 |
Why?
|
| Heparin | 2 | 1999 | 118 | 0.040 |
Why?
|
| Survival Rate | 2 | 2000 | 844 | 0.040 |
Why?
|
| Disease Management | 2 | 2013 | 235 | 0.040 |
Why?
|
| Streptokinase | 1 | 2000 | 6 | 0.040 |
Why?
|
| Platelet Count | 1 | 2000 | 26 | 0.040 |
Why?
|
| Curriculum | 2 | 2013 | 608 | 0.040 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2014 | 268 | 0.040 |
Why?
|
| Salvage Therapy | 1 | 2000 | 75 | 0.040 |
Why?
|
| Benchmarking | 2 | 2011 | 137 | 0.040 |
Why?
|
| Gonadal Steroid Hormones | 2 | 2010 | 36 | 0.040 |
Why?
|
| Diffusion of Innovation | 2 | 2010 | 58 | 0.040 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2000 | 126 | 0.040 |
Why?
|
| Constriction, Pathologic | 3 | 1994 | 130 | 0.040 |
Why?
|
| Shock, Cardiogenic | 1 | 2000 | 108 | 0.040 |
Why?
|
| Myocardial Contraction | 1 | 1999 | 88 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 2 | 1998 | 159 | 0.040 |
Why?
|
| Education, Medical, Graduate | 2 | 2013 | 348 | 0.040 |
Why?
|
| Catheters, Indwelling | 1 | 1998 | 67 | 0.030 |
Why?
|
| Risk | 2 | 2012 | 374 | 0.030 |
Why?
|
| Age Factors | 1 | 2000 | 1585 | 0.030 |
Why?
|
| Rest | 1 | 1994 | 45 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 1994 | 73 | 0.030 |
Why?
|
| Fish Oils | 1 | 1994 | 43 | 0.030 |
Why?
|
| Diastole | 1 | 1994 | 90 | 0.030 |
Why?
|
| Policy Making | 1 | 2014 | 48 | 0.030 |
Why?
|
| Coronary Circulation | 1 | 1994 | 55 | 0.030 |
Why?
|
| Educational Status | 1 | 1995 | 278 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 1994 | 602 | 0.020 |
Why?
|
| Incidence | 2 | 2002 | 1419 | 0.020 |
Why?
|
| Foundations | 1 | 2013 | 8 | 0.020 |
Why?
|
| Radiography | 1 | 1995 | 555 | 0.020 |
Why?
|
| Learning Curve | 1 | 2013 | 33 | 0.020 |
Why?
|
| Research Report | 1 | 2013 | 26 | 0.020 |
Why?
|
| Education, Medical | 2 | 2010 | 182 | 0.020 |
Why?
|
| Logistic Models | 3 | 2002 | 1270 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 794 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 1995 | 460 | 0.020 |
Why?
|
| Health Physics | 1 | 2011 | 6 | 0.020 |
Why?
|
| X-Rays | 1 | 2011 | 46 | 0.020 |
Why?
|
| Argentina | 1 | 2010 | 11 | 0.020 |
Why?
|
| Radiometry | 1 | 2011 | 39 | 0.020 |
Why?
|
| Disease-Free Survival | 2 | 2002 | 244 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2012 | 151 | 0.020 |
Why?
|
| Research Subjects | 1 | 1991 | 41 | 0.020 |
Why?
|
| Brazil | 1 | 2010 | 103 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 1991 | 117 | 0.020 |
Why?
|
| Informed Consent | 1 | 1991 | 141 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2011 | 158 | 0.020 |
Why?
|
| Swine | 2 | 1994 | 394 | 0.020 |
Why?
|
| Creatine Kinase | 1 | 2009 | 42 | 0.020 |
Why?
|
| Data Collection | 1 | 2011 | 382 | 0.020 |
Why?
|
| Troponin | 1 | 2009 | 39 | 0.020 |
Why?
|
| Observation | 1 | 2009 | 30 | 0.020 |
Why?
|
| Arteriosclerosis | 1 | 1989 | 32 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 2619 | 0.020 |
Why?
|
| Eicosapentaenoic Acid | 1 | 1989 | 18 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2009 | 125 | 0.020 |
Why?
|
| Hyperlipidemias | 1 | 1989 | 34 | 0.020 |
Why?
|
| Mentors | 1 | 2010 | 119 | 0.020 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2009 | 43 | 0.020 |
Why?
|
| Consensus | 1 | 2010 | 176 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2009 | 137 | 0.020 |
Why?
|
| Heart Diseases | 1 | 2010 | 223 | 0.020 |
Why?
|
| Blood Platelets | 1 | 1989 | 108 | 0.020 |
Why?
|
| Quality of Life | 1 | 1995 | 1259 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 856 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2007 | 90 | 0.020 |
Why?
|
| Cholesterol, LDL | 2 | 2002 | 104 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2009 | 223 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2007 | 178 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2012 | 706 | 0.020 |
Why?
|
| Child | 1 | 1996 | 4612 | 0.020 |
Why?
|
| Recurrence | 3 | 1994 | 657 | 0.010 |
Why?
|
| Pyrrolidines | 1 | 1985 | 13 | 0.010 |
Why?
|
| Calcium Channel Blockers | 1 | 1985 | 58 | 0.010 |
Why?
|
| Catheterization | 1 | 2005 | 111 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2010 | 593 | 0.010 |
Why?
|
| Biomarkers | 1 | 2009 | 1480 | 0.010 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2007 | 276 | 0.010 |
Why?
|
| Prosthesis Implantation | 1 | 2003 | 30 | 0.010 |
Why?
|
| Belgium | 1 | 2002 | 6 | 0.010 |
Why?
|
| Quebec | 1 | 2002 | 15 | 0.010 |
Why?
|
| Cholesterol, HDL | 1 | 2002 | 71 | 0.010 |
Why?
|
| Equipment Design | 1 | 2002 | 363 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2003 | 587 | 0.010 |
Why?
|
| Triglycerides | 1 | 2002 | 248 | 0.010 |
Why?
|
| Animals | 3 | 2007 | 21333 | 0.010 |
Why?
|
| Double-Blind Method | 2 | 1994 | 739 | 0.010 |
Why?
|
| Acute Disease | 1 | 2002 | 663 | 0.010 |
Why?
|
| Prognosis | 2 | 2002 | 1785 | 0.010 |
Why?
|
| Cognition | 1 | 2005 | 508 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2001 | 497 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2001 | 576 | 0.010 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2001 | 169 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2003 | 1016 | 0.010 |
Why?
|
| Emergency Treatment | 1 | 2000 | 55 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2000 | 208 | 0.010 |
Why?
|
| Whole Blood Coagulation Time | 1 | 1999 | 3 | 0.010 |
Why?
|
| Emergencies | 1 | 2000 | 123 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2001 | 740 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 2000 | 165 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1999 | 175 | 0.010 |
Why?
|
| Blood Vessels | 1 | 1999 | 63 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2002 | 6865 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 1999 | 296 | 0.010 |
Why?
|
| Blood Coagulation | 1 | 1998 | 41 | 0.010 |
Why?
|
| Massachusetts | 1 | 2002 | 2145 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2000 | 875 | 0.010 |
Why?
|
| Medical Staff, Hospital | 1 | 1995 | 59 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1994 | 128 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1993 | 105 | 0.010 |
Why?
|
| Heart Failure | 1 | 2000 | 957 | 0.010 |
Why?
|
| Heart | 1 | 1994 | 297 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 1995 | 433 | 0.010 |
Why?
|
| Therapeutic Human Experimentation | 1 | 1991 | 5 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1993 | 204 | 0.010 |
Why?
|
| Consent Forms | 1 | 1991 | 15 | 0.010 |
Why?
|
| Forecasting | 1 | 1992 | 230 | 0.010 |
Why?
|
| Reoperation | 1 | 1992 | 301 | 0.010 |
Why?
|
| Smoking | 1 | 1994 | 861 | 0.000 |
Why?
|
| Comprehension | 1 | 1991 | 138 | 0.000 |
Why?
|
| Apolipoproteins B | 1 | 1989 | 19 | 0.000 |
Why?
|
| Perfusion | 1 | 1986 | 75 | 0.000 |
Why?
|
| Bepridil | 1 | 1985 | 2 | 0.000 |
Why?
|
| Infusions, Parenteral | 1 | 1985 | 21 | 0.000 |
Why?
|
| Cardiac Output | 1 | 1985 | 28 | 0.000 |
Why?
|
| Vascular Resistance | 1 | 1985 | 47 | 0.000 |
Why?
|
| Heart Rate | 1 | 1985 | 331 | 0.000 |
Why?
|
| Blood Pressure | 1 | 1985 | 526 | 0.000 |
Why?
|